1
ALL1
Population Health Research InstituteYear
1
ALL1
2020DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
CANADA1
ALL1
Bayer AGTherapeutic Area
1
ALL1
Infections and Infectious DiseasesStudy Phase
1
ALL1
Phase IIIDeal Type
1
ALL1
PartnershipProduct Type
1
ALL1
Small moleculeDosage Form
0
ALLLead Product
1
ALL1
Chloroquine PhosphateTarget
0
ALLLead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $1.1 million
Deal Type : Partnership
Details : Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 21, 2020
Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $1.1 million
Deal Type : Partnership
LOOKING FOR A SUPPLIER?